genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm
News Oct 19, 2007
genOway reports the signing of a contract for up to $2 million in intended services with a leading biopharmaceutical company based in the United States of America.
Under the terms of this 2-year agreement, genOway will provide its client with customized genetically modified mouse lines tailored to the researchers’ needs. Moreover, this agreement can be increased to include additional models.
genOway has been chosen thanks to the company’s expertise and capacity to create highly sophisticated animal models by means of an industrialized production process.
"This contract is the second multi-million dollar deal of the year for genOway. It further confirms that the company is able to propose acceptable offers to large biopharmaceutical companies. genOway is proud to have been chosen by this company and we are very excited about the start of this collaboration" said Alexandre Fraichard, CEO of genOway.
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.